Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Am J Cardiovasc Drugs
; 8(2): 113-25, 2008.
Article
en En
| MEDLINE
| ID: mdl-18422394
ABSTRACT
Fondaparinux sodium (Arixtra) is a synthetic, sulfated pentasaccharide, selective factor Xa inhibitor that is indicated in Europe for preventing thrombus formation in patients with acute coronary syndromes (ACS; the focus of this review), including those with ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), or unstable angina.The large (n = 20,078), well designed OASIS-5 trial showed that subcutaneous fondaparinux 2.5 mg/day for
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Polisacáridos
/
Síndrome Coronario Agudo
/
Anticoagulantes
Límite:
Humans
Idioma:
En
Revista:
Am J Cardiovasc Drugs
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2008
Tipo del documento:
Article
País de afiliación:
Nueva Zelanda